Metabolic

Metabolic

Solving the "Ozempic Face" Dilemma: Wave Life Sciences Challenges the "Sarcopenic Status Quo" in Obesity with WVE-007 Success

In a crowded obesity market, WVE-007 emerges as a distinct 'Body Composition' asset, offering significant visceral fat reduction and lean mass gains that defy the typical GLP-1 trajectory. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and

Metabolic

Structure's Aleniglipron: Strong Data, Slower Timeline in the Oral GLP-1 Race

Phase 2b results confirm high efficacy and safety, but the pivot to a slower titration protocol pushes Phase 3 to mid-2026, widening the gap with lead competitors. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute

Metabolic

Akero's Efruxifermin: High Efficacy Meets High Maintenance in MASH Landscape

Phase 2b data confirms potent cirrhosis reversal, but safety signals may limit real-world adoption. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * Clinical Analysis: Efruxifermin in F4 MASH New data from Akero Therapeutics&

Metabolic

Altimmune’s Pemvidutide Achieves 59.1% MASH Resolution: A Potent "Defatting" Engine Faces the Fibrosis Lag Challenge

Phase 2b IMPACT trial data confirms best-in-class liver fat reduction, but a missed 24-week fibrosis endpoint necessitates a strategic pivot for Phase 3 design. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * What